Sicart Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sicart Associates’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,103	Closed	-$414K	–	77
2025 Q1	$414K	Sell	5,103 -200	-4%	-$17.9K	0.14%	53
2024 Q4	$478K	Hold	5,303	–	–	0.17%	51
2024 Q3	$524K	Buy	5,303 +200	+4%	+$19.6K	0.18%	50
2024 Q2	$473K	Hold	5,103	–	–	0.18%	52
2024 Q1	$484K	Buy	5,103 +2,783	+120%	+$258K	0.18%	52
2023 Q4	$207K	Buy	+2,320	New	+$172K	0.08%	67
2022 Q2	–	Sell	-2,320	Closed	-$209K	–	94
2022 Q1	$209K	Hold	2,320	–	–	0.05%	84
2021 Q4	$263K	Sell	2,320 -30	-1%	-$3.62K	0.07%	80
2021 Q3	$295K	Hold	2,350	–	–	0.08%	87
2021 Q2	$318K	Hold	2,350	–	–	0.08%	90
2021 Q1	$319K	Hold	2,350	–	–	0.08%	82
2020 Q4	$331K	Hold	2,350	–	–	0.08%	85
2020 Q3	$262K	Hold	2,350	–	–	0.08%	88
2020 Q2	$263K	Buy	+2,350	New	+$231K	0.08%	90
2020 Q1	–	Sell	-2,350	Closed	-$224K	–	123
2019 Q4	$224K	Buy	+2,350	New	+$203K	0.07%	98
2019 Q3	–	Sell	-3,350	Closed	-$294K	–	119
2019 Q2	$294K	Sell	3,350 -1,200	-26%	-$102K	0.12%	72
2019 Q1	$412K	Sell	4,550 -1,305	-22%	-$111K	0.17%	61
2018 Q4	$420K	Hold	5,855	–	–	0.2%	61
2018 Q3	$561K	Hold	5,855	–	–	0.27%	56
2018 Q2	$557K	Sell	5,855 -1,305	-18%	-$120K	0.29%	58
2018 Q1	$628K	Hold	7,160	–	–	0.38%	55
2017 Q4	$608K	Hold	7,160	–	–	0.32%	62
2017 Q3	$620K	Hold	7,160	–	–	0.44%	48
2017 Q2	$553K	Buy	7,160 +1,200	+20%	+$85.1K	0.4%	50
2017 Q1	$413K	Buy	+5,960	New	+$400K	0.3%	66

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sicart Associates's XBI Position: Q2 2025 in Review

Sicart Associates sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 5,103 shares — an estimated $414K sold.

Sicart Associates first reported a position in XBI in Q1 2017 and held it in 25 quarters. The position peaked at $628K in Q1 2018. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

Sicart Associates reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
Sicart Associates sold 5,103 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $414K.
Sicart Associates first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 25 quarters.
Sicart Associates's State Street SPDR S&P Biotech ETF position peaked at $628K in Q1 2018.
625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on Sicart Associates's 13F filing for Q2 2025, filed 18 Jul 2025.